TrialPath
Recruiting

A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis

NCT07845487 · Palisade Bio
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Induction and Maintenance Therapy With PALI-2108 in Participants With Moderately to Severely Active Ulcerative Colitis
About this study
The ASCENTRA-UC study is a phase 2 study testing PALI-2108 in patients with moderate to severe ulcerative colitis. Doses of drug will be compared against a placebo to see how well it works, how safe it is, and how the body responds to it.
Eligibility criteria
Key Inclusion Criteria: * Documented clinical diagnosis of UC for ≥ 3 months prior to Screening. The diagnosis of UC must be confirmed by endoscopic and histologic evidence. * If a histopathology report is not available in the source records, a biopsy for a local histopathology evaluation (to obtain a report) can be obtained during the screening endoscopy procedure. * Moderately to severely active UC, defined as: * mMS of 5 to 9 (inclusive), AND * ES ≥ 2, AND * RB ≥ 1. * Participants must satisfy at least one of the criteria listed under item a OR at least one of the criteria listed under item b: a. History of inadequate response or loss of response, or intolerance to at least one prior UC therapy, defined as: i. Oral prednisone ≥ 40 mg/day (or equivalent) or budesonide ≥ 9 mg/day for ≥ 2 weeks. ii. Corticosteroid dependence: unable to taper \< 10 mg/day prednisone equivalent within 3 months, or relapse within 3 months of discontinuation. iii. Immunosuppressants: azathioprine ≥ 2 mg/kg/day, 6-mercaptopurine (6-MP) ≥ 1.0 mg/kg/day (or therapeutic 6-thioguanine nucleotide \[6-TGN\] level) for ≥ 12 weeks, or methotrexate ≥ 15 mg/week subcutaneous or intramuscular. iv. Approved advanced therapies at the approved labelled dose: 1. Anti-tumor necrosis factor (TNF), anti-integrin (vedolizumab), or anti-IL-12/23 for at least 8 weeks; anti-IL 23 for at least 12 weeks. 2. Janus kinase (JAK) inhibitor for at least 8 weeks; sphingosine-1-phosphate receptor (S1PR) modulator for at least 12 weeks. Note: Demonstration of intolerance requires no minimum dose nor duration of use. b. Currently receiving one or more of the following treatments: i. Stable oral prednisone at ≤ 20 mg/day (or equivalent) or budesonide ≤ 9 mg for ≥ 2 weeks prior to randomization. ii. Stable dose of thiopurine (azathioprine or 6-MP) for ≥ 4 weeks prior to randomization, and have started the treatment ≥ 12 weeks prior to randomization. iii. Stable dose of oral aminosalicylates for ≥ 2 weeks prior to randomization. Key Exclusion Criteria:• Diagnosis of Crohn's disease or IBD-Unclassified (IBD-U; indeterminate colitis) or a history of ischemic colitis or radiation colitis. * UC limited to rectum (\< 15 cm from anal verge). * Any prior history of suicidal behavior (actual, interrupted, aborted attempt, or preparatory acts). * Columbia-Suicide Severity Rating Scale (C-SSRS) suicidal ideation type 4 or 5, or any active suicidal ideation with some intent to act. * Severe depression at Screening based on a validated scale threshold (e.g., Patient Health Questionnaire-9 \[PHQ-9\] ≥ 20, or PHQ-9 item 9 \> 0) at Screening. * Failure or intolerance of \> 3 classes of approved advanced therapies or \> 4 approved individual advanced therapies.
Study design
Enrollment target: 204 participants
Allocation: randomized
Masking: quadruple
Age groups: adult, older_adult
Timeline
Starts: 2026-08-28
Estimated completion: 2028-06
Last updated: 2026-11-12
Interventions
Drug: PALI-2108Drug: PALI-2108Drug: Placebo
Primary outcomes
  • • Proportion of participants with clinical remission using the 3-component modified Mayo Score (mMS) at Week 12. (Week 12)
Sponsor
Palisade Bio · industry
All locations (114)
Site US-022Recruiting
Sun City, Arizona, United States
Site US-018Recruiting
San Diego, California, United States
Site US-028Recruiting
Bristol, Connecticut, United States
Site US-026Recruiting
Orlando, Florida, United States
Site US-005Recruiting
Des Plaines, Illinois, United States
Site US-007Recruiting
Glenview, Illinois, United States
Site US-020Recruiting
Gurnee, Illinois, United States
Site US-008Recruiting
Baton Rouge, Louisiana, United States
Site US-011Recruiting
Mandeville, Louisiana, United States
Site US-010Recruiting
Tupelo, Mississippi, United States
Site US-006Recruiting
St Louis, Missouri, United States
Site US-014Recruiting
Clifton, New Jersey, United States
Site US-002Recruiting
Albany, New York, United States
Site US-016Recruiting
Rochester, New York, United States
Site US-025Recruiting
Brunswick, Ohio, United States
Site US-023Recruiting
Dayton, Ohio, United States
Site US-027Recruiting
Westlake, Ohio, United States
Site US-019Recruiting
Providence, Rhode Island, United States
Site US-003Recruiting
Cordova, Tennessee, United States
Site US-024Recruiting
Garland, Texas, United States
Site US-009Recruiting
Georgetown, Texas, United States
Site US-030Recruiting
Houston, Texas, United States
Site US-015Recruiting
Lubbock, Texas, United States
Site US-017Recruiting
Mansfield, Texas, United States
Site US-001Recruiting
Southlake, Texas, United States
Site US-004Recruiting
Tyler, Texas, United States
Site US-013Recruiting
Richmond, Virginia, United States
Site US-021Recruiting
Bellevue, Washington, United States
Site US-029Recruiting
Tacoma, Washington, United States
Site US-012Recruiting
Milwaukee, Wisconsin, United States
Site CA-005Not Yet Recruiting
Calgary, Alberta, Canada
Site CA-004Not Yet Recruiting
Edmonton, Alberta, Canada
Site CA-006Not Yet Recruiting
Greater Sudbury, Ontario, Canada
Site CA-003Not Yet Recruiting
London, Ontario, Canada
Site CA-002Not Yet Recruiting
Scarborough Village, Ontario, Canada
Site CA-007Not Yet Recruiting
Montreal, Quebec, Canada
Site CA-001Not Yet Recruiting
Montreal, Quebec, Canada
Site CZ-005Not Yet Recruiting
Brno, Czechia
Site CZ-002Not Yet Recruiting
Brno, Czechia
Site CZ-008Not Yet Recruiting
Havířov, Czechia
Site CZ-006Not Yet Recruiting
Hradec Králové, Czechia
Site CZ-007Not Yet Recruiting
Prague, Czechia
Site CZ-004Not Yet Recruiting
Slaný, Czechia
Site FR-003Not Yet Recruiting
Amiens, France
Site FR-005Not Yet Recruiting
Clermont-Ferrand, France
Site FR-002Not Yet Recruiting
Neuilly-sur-Seine, France
Site FR-001Not Yet Recruiting
Nice, France
Site FR-004Not Yet Recruiting
Saint-Priest-en-Jarez, France
Site GE-003Not Yet Recruiting
Batumi, Quebec, Georgia
Site GE-007Not Yet Recruiting
Tbilisi, Quebec, Georgia
Site GE-002Not Yet Recruiting
Tbilisi, Quebec, Georgia
Site GE-004Not Yet Recruiting
Tbilisi, Quebec, Georgia
Site GE-008Not Yet Recruiting
Tbilisi, Quebec, Georgia
Site GE-001Not Yet Recruiting
Tbilisi, Quebec, Georgia
Site GE-005Not Yet Recruiting
Tbilisi, Quebec, Georgia
Site GE-006Not Yet Recruiting
Tbilisi, Quebec, Georgia
Site HU-005Not Yet Recruiting
Budapest, Hungary
Site HU-002Not Yet Recruiting
Budapest, Hungary
Site HU-001Not Yet Recruiting
Budapest, Hungary
Site HU-004Not Yet Recruiting
Debrecen, Hungary
Site HU-007Not Yet Recruiting
Gyöngyös, Hungary
Site HU-006Not Yet Recruiting
Tatabánya, Hungary
Site HU-003Not Yet Recruiting
Veszprém, Hungary
Site IT-002Not Yet Recruiting
Bari, Italy
Site IT-004Not Yet Recruiting
Bologna, Italy
Site IT-007Not Yet Recruiting
Matera, Italy
Site IT-009Not Yet Recruiting
Negrar, Italy
Site IT-001Not Yet Recruiting
Rome, Italy
Site IT-003Not Yet Recruiting
Rome, Italy
Site IT-008Not Yet Recruiting
Rome, Italy
Site IT-006Not Yet Recruiting
Rozzano, Italy
Site IT-005Not Yet Recruiting
San Giovanni Rotondo, Italy
Site IT-010Not Yet Recruiting
Turin, Italy
Site LV-003Not Yet Recruiting
Liepāja, Latvia
Site LV-002Not Yet Recruiting
Riga, Latvia
Site LV-001Not Yet Recruiting
Riga, Latvia
Site PL-014Not Yet Recruiting
Bydgoszcz, Poland
Site PL-005Not Yet Recruiting
Elblag, Poland
Site PL-006Not Yet Recruiting
Katowice, Poland
Site PL-022Not Yet Recruiting
Kielce, Poland
Site PL-002Not Yet Recruiting
Krakow, Poland
Site PL-016Not Yet Recruiting
Krakow, Poland
Site PL-020Not Yet Recruiting
Kłodzko, Poland
Site PL-021Not Yet Recruiting
Lodz, Poland
Site PL-004Not Yet Recruiting
Lublin, Poland
Site PL-008Not Yet Recruiting
Nowy Targ, Poland
Site PL-018Not Yet Recruiting
Opole, Poland
Site PL-003Not Yet Recruiting
Poznan, Poland
Site PL-010Not Yet Recruiting
Sopot, Poland
Site PL-012Not Yet Recruiting
Staszów, Poland
Site PL-001Not Yet Recruiting
Szczecin, Poland
Site PL-015Not Yet Recruiting
Szczecin, Poland
Site PL-007Not Yet Recruiting
Torun, Poland
Site PL-019Not Yet Recruiting
Tychy, Poland
Site PL-017Not Yet Recruiting
Warsaw, Poland
Site PL-013Not Yet Recruiting
Warsaw, Poland
Site PL-009Not Yet Recruiting
Wroclaw, Poland
Site PL-011Not Yet Recruiting
Wroclaw, Poland
Site RO-001Not Yet Recruiting
Bucharest, Romania
Site RO-003Not Yet Recruiting
Bucharest, Romania
Site RO-006Not Yet Recruiting
Constanța, Romania
Site RO-004Not Yet Recruiting
Ploieşti, Romania
Site RO-002Not Yet Recruiting
Timișoara, Romania
Site RO-005Not Yet Recruiting
Timișoara, Romania
Site RS-006Not Yet Recruiting
Belgrade, Serbia
Site RS-001Not Yet Recruiting
Belgrade, Serbia
Site RS-002Not Yet Recruiting
Belgrade, Serbia
Site RS-004Not Yet Recruiting
Leskovac, Serbia
Site RS-005Not Yet Recruiting
Užice, Serbia
Site RS-003Not Yet Recruiting
Zrenjanin, Serbia
Site SK-001Not Yet Recruiting
Banská Bystrica, Slovakia
Site SK-004Not Yet Recruiting
Košice, Slovakia
Site SK-002Not Yet Recruiting
Prešov, Slovakia
Site SK-006Not Yet Recruiting
Zvolen, Slovakia